Latest news with #EksoBionics
Yahoo
29-07-2025
- Business
- Yahoo
Ekso Bionics Holdings Inc (EKSO) Q2 2025 Earnings Call Highlights: Navigating Revenue Decline ...
Revenue: $2.1 million for Q2 2025, down from $5 million in Q2 2024. Gross Profit: $800,000 for Q2 2025, compared to $2.6 million in Q2 2024. Gross Margin: Approximately 40% for Q2 2025, down from 53% in Q2 2024. Operating Expenses: $4.8 million for Q2 2025, a 4% decrease from $5 million in Q2 2024. Net Loss: $2.7 million for Q2 2025, or $1.24 per share, compared to $2.4 million, or $1.99 per share, in Q2 2024. Cash and Restricted Cash: $5.2 million as of June 30, 2025. Personal Health Product Revenue Growth: More than 50% increase in the first half of 2025 compared to the same period in 2024. Warning! GuruFocus has detected 2 Warning Signs with EKSO. Release Date: July 28, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Ekso Bionics Holdings Inc (NASDAQ:EKSO) is confident in closing a significant portion of deferred multi-device Enterprise Health sales by year-end. The company has launched eksoUniversity, a virtual platform providing continuing education courses to physical therapists, which could generate incremental revenue. Personal Health product revenues grew by more than 50% year-over-year in the first half of 2025. Ekso Bionics Holdings Inc (NASDAQ:EKSO) has partnered with PRIA Healthcare to enhance market access and commercialization of the Ekso Indego Personal device. The company is leveraging AI capabilities through the NVIDIA Connect program to enhance its exoskeleton technology platforms. Negative Points Ekso Bionics Holdings Inc (NASDAQ:EKSO) experienced a significant revenue decline in Q2 2025, with revenues dropping to $2.1 million from $5 million in Q2 2024. Gross profit and gross margin decreased due to lower Enterprise Health device sales and increased shipping costs. The company reported a net loss of $2.7 million for Q2 2025, compared to a net loss of $2.4 million in Q2 2024. There are short-term delays in completing significant multi-device Enterprise Health sales, impacting revenue. A small percentage of US customers have delayed purchases due to loss of federal grants and economic uncertainties. Q & A Highlights Q: Can you quantify the deferred sales on the Enterprise Health side and how much you expect in the back half of the year? A: Scott Davis, CEO, explained that two multiunit device sales were delayed, one international order due to regulatory challenges expected to occur in 2025, and a North American IDN order expected in Q3, totaling about $1.4 million. Q: When do you expect the Indego Personal to overtake the Enterprise Health business? A: Scott Davis, CEO, indicated that while Indego Personal represented about 10% of revenue in 2024, it is expected to contribute closer to 25% in 2025. By 2027, it is anticipated to overtake the Enterprise Health business. Q: How is the process of nailing down the patient profile and claims for Indego Personal progressing? A: Scott Davis, CEO, noted progress in the appeals process, with positive outcomes reaffirming medical necessity. They are working with DME and O&P partners to ensure strong claims submissions, aiming for routine approvals. Q: Will eksoUniversity focus solely on exoskeletons, or will it include other content? A: Scott Davis, CEO, stated that while initial courses focus on exoskeleton technology, eksoUniversity will cover a wide range of neuro rehabilitation topics, leveraging contributions from neuro PTs within their ecosystem. Q: What steps are being taken to ensure growth in enterprise sales, and how long will it take? A: Scott Davis, CEO, mentioned that they are working to close deferred deals and exploring options like third-party financial partners to help customers with budget constraints. They are optimistic about pulling in deferred deals in Q3. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
12-06-2025
- Business
- Yahoo
Exoskeleton Market Research and Global Forecast Report 2025-2030: Powered Exoskeletons Lead Growth with Robust Investment Activities, Industrial Adoption Amplifies Expansion
The exoskeleton market is projected to grow from USD 0.56 billion in 2025 to USD 2.03 billion by 2030, with a CAGR of 29.4%. Exoskeletons enhance mobility for those with physical impairments and reduce industrial workers' strain, boosting demand in healthcare and manufacturing. The rise in the elderly population and home rehabilitation heightens this need. Technological advancements, including AI and improved materials, are enhancing exoskeleton functionality and availability. Significant investments, such as those in German Bionic and Verve Motion, highlight the industry's growth potential. Key players include Ekso Bionics, Ottobock, and CYBERDYNE Inc. Exoskeleton Market Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Exoskeleton Market by Component (Sensors, Actuators, Power Systems, Controllers, Software), Functionality (Assistive, Rehabilitative, Augmentative, Preventive), Type (Powered, Passive, Hybrid), Body Part (Lower, Upper, Full Body) - Global Forecast to 2030" has been added to offering. The exoskeleton market is anticipated to grow significantly, from USD 0.56 billion in 2025 to USD 2.03 billion by 2030, with a robust CAGR of 29.4% This surge is driven by its expanding integration into healthcare and manufacturing sectors, aiding mobility for physically impaired individuals while reducing industrial workers' physical strain. An aging population and increased home care rehabilitation further propel the demand. The evolution of technology, including AI, sensors, and lightweight materials, enhances the affordability, accessibility, and performance of exoskeletons. Investment from both public and private sectors will continue to bolster product innovation and market growth. Key players in the market include Ekso Bionics (US), Ottobock (Germany), DIH Medical (Switzerland), Comau (Italy), Myomo Inc. (US), CYBERDYNE Inc. (Japan), Lifeward Ltd. (Israel), Hyundai Motor Group Robotics LAB. (South Korea), B-Temia (Canada), Rex Bionics Ltd. (New Zealand), among Exoskeletons Gaining Momentum The powered exoskeleton sector is witnessing robust growth, exemplified by the strategic investments and increased investor confidence in its commercial viability. German Bionic, an innovator in electrically powered exoskeletons, secured over USD 16.3 million in an extended Series A funding round in December 2023. This investment aims to enhance collaboration with Mubea and scale production for better market deployment. Additionally, Verve Motion, a Cambridge-based startup specializing in robotic exosuits, raised USD 20 million in a Series B funding round to further its market reach. These developments highlight the strategic investment in powered exoskeleton technology, poised to revolutionize industrial automation, injury prevention, and workforce Sector's Rapid Adoption The industrial sector is increasingly adopting exoskeletons to boost worker safety, mitigate fatigue, and enhance productivity. They are essential in industries such as manufacturing, logistics, and assembly lines, where repetitive tasks are prevalent. Exoskeletons help mitigate musculoskeletal injuries by supporting the lower back, shoulders, and legs, thereby reducing the occupational health costs and improving Leading Europe Germany leads the European exoskeleton market with strong industrial demand and innovation in healthcare, supported by significant private investments. Its robust manufacturing and logistics sectors actively integrate exoskeletons to enhance workforce efficiency and reduce musculoskeletal injuries. Companies like German Bionic are at the forefront, raising over USD 16.3 million to advance their product offerings, with models like Apogee and Apogee+ significantly impacting logistics, retail, and healthcare sectors with their ergonomic Insights Include: Analysis of market drivers, restraints, opportunities, and challenges. Insights into upcoming technologies, R&D activities, and product launches. Comprehensive information on lucrative markets. In-depth competitive assessments and strategic analysis of leading players. Key Attributes: Report Attribute Details No. of Pages 255 Forecast Period 2025 - 2030 Estimated Market Value (USD) in 2025 $0.56 Billion Forecasted Market Value (USD) by 2030 $2.03 Billion Compound Annual Growth Rate 29.4% Regions Covered Global Market Dynamics Drivers Rising Demand for Robotic Rehabilitation Solutions From Healthcare Sector Increased Adoption in Industrial and Manufacturing Sectors Increased FDA Approvals for Medical Exoskeletons Challenges High Cost of Ownership Comfort and Movement Interference for Workers Power Supply Limitations and Operational Downtime Opportunities Integration of Exoskeletons With AI and IoT Technologies Increasing Adoption of Exoskeletons in Military and Defense Sectors Case Studies Enhancing Worker Ergonomics and Productivity At John Deere With Comau's Mate-Xt Wearable Exoskeleton Enhancing Logistics Operations and Worker Well-Being At Fiege Group With German Bionic AI-Powered Exoskeleton Technology Enhancing Worker Safety and Productivity in Tunnel Construction At Granite Construction With Levitate Technologies Exoskeletons Reducing Physical Strain in Truck Maintenance At Man Truck & Bus With Help of Suitx Technology by Ottobock Ford Motor Company Enhances Worker Safety and Reduces Injuries With Ekso Bionics Eksovest Company Profiles Ekso Bionics Ottobock DIH Medical Comau Myomo Inc. Cyberdyne Inc. Lifeward Ltd. Hyundai Motor Group Robotics Lab. B-Temia Rex Bionics Ltd. Able Human Motion Laevo Exoskeletons German Bionic Systems GmbH Levitate Technologies, Inc. Fourier Trexo Robotics Wandercraft Agade Europe Technologies Archelis Inc. P&S Mechanics Co., Ltd. Rb3D Japet Medical Devices Proteso S.R.L. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Exoskeleton Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
12-06-2025
- Business
- Yahoo
Exoskeleton Market Research and Global Forecast Report 2025-2030: Powered Exoskeletons Lead Growth with Robust Investment Activities, Industrial Adoption Amplifies Expansion
The exoskeleton market is projected to grow from USD 0.56 billion in 2025 to USD 2.03 billion by 2030, with a CAGR of 29.4%. Exoskeletons enhance mobility for those with physical impairments and reduce industrial workers' strain, boosting demand in healthcare and manufacturing. The rise in the elderly population and home rehabilitation heightens this need. Technological advancements, including AI and improved materials, are enhancing exoskeleton functionality and availability. Significant investments, such as those in German Bionic and Verve Motion, highlight the industry's growth potential. Key players include Ekso Bionics, Ottobock, and CYBERDYNE Inc. Exoskeleton Market Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Exoskeleton Market by Component (Sensors, Actuators, Power Systems, Controllers, Software), Functionality (Assistive, Rehabilitative, Augmentative, Preventive), Type (Powered, Passive, Hybrid), Body Part (Lower, Upper, Full Body) - Global Forecast to 2030" has been added to offering. The exoskeleton market is anticipated to grow significantly, from USD 0.56 billion in 2025 to USD 2.03 billion by 2030, with a robust CAGR of 29.4% This surge is driven by its expanding integration into healthcare and manufacturing sectors, aiding mobility for physically impaired individuals while reducing industrial workers' physical strain. An aging population and increased home care rehabilitation further propel the demand. The evolution of technology, including AI, sensors, and lightweight materials, enhances the affordability, accessibility, and performance of exoskeletons. Investment from both public and private sectors will continue to bolster product innovation and market growth. Key players in the market include Ekso Bionics (US), Ottobock (Germany), DIH Medical (Switzerland), Comau (Italy), Myomo Inc. (US), CYBERDYNE Inc. (Japan), Lifeward Ltd. (Israel), Hyundai Motor Group Robotics LAB. (South Korea), B-Temia (Canada), Rex Bionics Ltd. (New Zealand), among Exoskeletons Gaining Momentum The powered exoskeleton sector is witnessing robust growth, exemplified by the strategic investments and increased investor confidence in its commercial viability. German Bionic, an innovator in electrically powered exoskeletons, secured over USD 16.3 million in an extended Series A funding round in December 2023. This investment aims to enhance collaboration with Mubea and scale production for better market deployment. Additionally, Verve Motion, a Cambridge-based startup specializing in robotic exosuits, raised USD 20 million in a Series B funding round to further its market reach. These developments highlight the strategic investment in powered exoskeleton technology, poised to revolutionize industrial automation, injury prevention, and workforce Sector's Rapid Adoption The industrial sector is increasingly adopting exoskeletons to boost worker safety, mitigate fatigue, and enhance productivity. They are essential in industries such as manufacturing, logistics, and assembly lines, where repetitive tasks are prevalent. Exoskeletons help mitigate musculoskeletal injuries by supporting the lower back, shoulders, and legs, thereby reducing the occupational health costs and improving Leading Europe Germany leads the European exoskeleton market with strong industrial demand and innovation in healthcare, supported by significant private investments. Its robust manufacturing and logistics sectors actively integrate exoskeletons to enhance workforce efficiency and reduce musculoskeletal injuries. Companies like German Bionic are at the forefront, raising over USD 16.3 million to advance their product offerings, with models like Apogee and Apogee+ significantly impacting logistics, retail, and healthcare sectors with their ergonomic Insights Include: Analysis of market drivers, restraints, opportunities, and challenges. Insights into upcoming technologies, R&D activities, and product launches. Comprehensive information on lucrative markets. In-depth competitive assessments and strategic analysis of leading players. Key Attributes: Report Attribute Details No. of Pages 255 Forecast Period 2025 - 2030 Estimated Market Value (USD) in 2025 $0.56 Billion Forecasted Market Value (USD) by 2030 $2.03 Billion Compound Annual Growth Rate 29.4% Regions Covered Global Market Dynamics Drivers Rising Demand for Robotic Rehabilitation Solutions From Healthcare Sector Increased Adoption in Industrial and Manufacturing Sectors Increased FDA Approvals for Medical Exoskeletons Challenges High Cost of Ownership Comfort and Movement Interference for Workers Power Supply Limitations and Operational Downtime Opportunities Integration of Exoskeletons With AI and IoT Technologies Increasing Adoption of Exoskeletons in Military and Defense Sectors Case Studies Enhancing Worker Ergonomics and Productivity At John Deere With Comau's Mate-Xt Wearable Exoskeleton Enhancing Logistics Operations and Worker Well-Being At Fiege Group With German Bionic AI-Powered Exoskeleton Technology Enhancing Worker Safety and Productivity in Tunnel Construction At Granite Construction With Levitate Technologies Exoskeletons Reducing Physical Strain in Truck Maintenance At Man Truck & Bus With Help of Suitx Technology by Ottobock Ford Motor Company Enhances Worker Safety and Reduces Injuries With Ekso Bionics Eksovest Company Profiles Ekso Bionics Ottobock DIH Medical Comau Myomo Inc. Cyberdyne Inc. Lifeward Ltd. Hyundai Motor Group Robotics Lab. B-Temia Rex Bionics Ltd. Able Human Motion Laevo Exoskeletons German Bionic Systems GmbH Levitate Technologies, Inc. Fourier Trexo Robotics Wandercraft Agade Europe Technologies Archelis Inc. P&S Mechanics Co., Ltd. Rb3D Japet Medical Devices Proteso S.R.L. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Exoskeleton Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Business Insider
31-05-2025
- Business
- Business Insider
Ekso Bionics trading halted, news pending
19:50 EDT Ekso Bionics (EKSO) trading halted, news pending Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Business Insider
20-05-2025
- Business
- Business Insider
Ekso Bionics to effect 1-for-15 reverse stock split
Ekso Bionics announced that it will effect a reverse stock split of shares of its common stock at a ratio of 1-for-15, effective as of May 27at 12:01 a.m. Pacific time. The company's common stock will open for trading on Nasdaq Capital Market on May 27 on a split-adjusted basis under the existing symbol (EKSO). The company's common stock will trade under a new CUSIP number 282644 400 upon the effectiveness of the reverse stock split. Upon the effectiveness of the reverse stock split, the number of shares of the company's outstanding common stock will decrease from approximately 35,289,695 pre-split shares to approximately 2,352,646 post-split shares, with no change in par value per share. The reverse stock split was approved by the company's shareholders at a special meeting held on May 16, 2025, and is primarily intended to raise the per share trading price of the Company's common stock and, in particular, enable the Company to regain compliance with the minimum bid price requirement for maintaining its listing on The Nasdaq Capital Market. To regain compliance, the closing bid price of the company's common stock must be at least $1.00 for a minimum of ten consecutive trading days. Confident Investing Starts Here:
